SCHEMBL8305215

SCHEMBL8305215

COC(c1ccccc1)C1COC(=O)O1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 2/20 0.45
IDO1 P14902 3/20 0.35
SLC6A3 Q01959 4/20 0.35
SLC6A2 P23975 3/20 0.35
SLC6A4 P31645 3/20 0.35
HSD17B2 P37059 1/20 0.34
ALDH1A1 P00352 1/20 0.33
FPR2 P25090 1/20 0.33
PROKR1 Q8TCW9 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP19A1 P11511 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8308522 1.00 EPHX1 (0.45) EPHX1IDO1SLC6A3SLC6A2SLC6A4
SCHEMBL7294198 0.77 EPHX1 (0.55) EPHX1IDO1SLC6A3SLC6A2SLC6A4
SCHEMBL28574749 0.70 EPHX1 (0.38) EPHX1SLC6A3SLC6A2SLC6A4HSD17B2
SCHEMBL21175346 0.70 EPHX1 (0.44) EPHX1IDO1SLC6A3SLC6A2SLC6A4
SCHEMBL14895451 0.70 CYP1A2 (0.37) ALDH1A1KMT2ACYP1A2
SCHEMBL28573814 0.69 EPHX1 (0.40) EPHX1SLC6A3SLC6A2SLC6A4HSD17B2
Isopropylbenzene SCHEMBL28915614 0.69 GRM2 (0.36) ALDH1A1
SCHEMBL28451662 0.68
SCHEMBL10067167 0.68 EPHX1 (0.45) EPHX1IDO1SLC6A3SLC6A2SLC6A4
SCHEMBL6526560 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0835254-B1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1999-09-01 EP claimed
US-5843975-A Oxazolidinone derivatives, their preparation and therapeutical use SYNTHELABO (FR) 1998-12-01 US claimed
EP-0835254-A1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1998-04-15 EP claimed
WO-1996038444-A1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1996-12-05 WO claimed
EP-2771315-B1 METHOD FOR PREPARING A COMPOUND COMPRISING AT LEAST ONE beta-HYDROXY-URETHANE UNIT AND/OR AT LEAST ONE gamma-HYDROXY-URETHANE UNIT SOCIÉTÉ D EXPL GÉNÉRALE DE PRODUITS IND S E G SAS (FR) 2016-04-13 EP disclosed
US-20140378648-A1 METHOD FOR PREPARING A COMPOUND COMPRISING AT LEAST ONE BETA-HYDROXY-URETHANE UNIT AND/OR AT LEAST ONE UPSILON-HYDROXY-URETHANE UNIT SOULES AURÉLIEN (FR) 2014-12-25 US disclosed
EP-2771315-A1 METHOD FOR PREPARING A COMPOUND COMPRISING AT LEAST ONE beta-HYDROXY-URETHANE UNIT AND/OR AT LEAST ONE gamma-HYDROXY-URETHANE UNIT Societe d'Exploitation Generale de Produits Industriels - S.E.G (SAS) (FR) 2014-09-03 EP disclosed
WO-2013060950-A1 METHOD FOR PREPARING A COMPOUND COMPRISING AT LEAST ONE β-HYDROXY-URETHANE UNIT AND/OR AT LEAST ONE ϒ-HYDROXY-URETHANE UNIT SOCIETE D'EXPLOITATION GENERALE DE PRODUITS INDUSTRIELS - S.E.G. (SAS) (FR) 2013-05-02 WO disclosed
EP-0835254-B1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1999-09-01 EP disclosed
US-5843975-A Oxazolidinone derivatives, their preparation and therapeutical use SYNTHELABO (FR) 1998-12-01 US disclosed
EP-0835254-A1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1998-04-15 EP disclosed
WO-1996038444-A1 OXAZOLIDINONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE SYNTHELABO (FR) 1996-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378648-A1 METHOD FOR PREPARING A COMPOUND COMPRISING AT LEAST ONE BETA-HYDROXY-URETHANE UNIT AND/OR AT LEAST ONE UPSILON-HYDROXY-URETHANE UNIT OTUB1, UCHL1, UBE2E1 EPHX1 857/4885IDO1 692/4885SLC6A3 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.